Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 13Unknown 4Terminated 4Withdrawn 2Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Gynecologic 1

Conditions

Colorectal Neoplasms 21Squamous Cell Carcinoma of Head and Neck 16Colonic Neoplasms 11Rectal Neoplasms 8Head and Neck Neoplasms 8Neoplasm Metastasis 6Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Pancreatic Neoplasms 2Esophageal Neoplasms 2Chordoma 2Breast Neoplasms 2Unresectable Colorectal Cancer 1Tongue Neoplasms 1Thymoma 1Solid Tumor, Adult 1Solid Cancer 1Skin Neoplasms 1Rectal Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Noonan Syndrome 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Metastatic Colorectal Adenocarcinoma 1Lymphoid Interstitial Pneumonia 1Lung Neoplasms 1Laryngeal Neoplasms 1Laryngeal Diseases 1

Interventions

Carboplatin 12Paclitaxel 11pembrolizumab 10Fluorouracil 10Oxaliplatin 9Radiotherapy 7Nivolumab 7Leucovorin 7Cisplatin 6Radiotherapy, Intensity-Modulated 5Magnetic Resonance Spectroscopy 5Taxes 4durvalumab 3Trastuzumab 3Docetaxel 3Capecitabine 3tislelizumab 2relatlimab 2Surgical Procedures, Operative 2Standard of Care 2Specimen Handling 2Radiation 2Proton Therapy 2Practice Guidelines as Topic 2Irinotecan 2Immune Checkpoint Inhibitors 2Fluorodeoxyglucose F18 2Drug Therapy 2Cetuximab 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Esophageal Neoplasms × Cetuximab × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT04229459 2026-01-14

Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.

Rabin Medical Center

Phase 2 Active not recruiting
12 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡